FDA Alerts

bone disorders
bone disorders
New Osteoporosis Treatment Approved by the FDA
05/01/2017
The US Food and Drug Administration has approved a new treatment for osteoporosis for postmenopausal women at a high risk for fracture.
05/01/2017
Lung cancer
Lung cancer
New Option for Non-Small Cell Lung Cancer Approved
04/28/2017
The FDA has approved a new drug for the treatment of patients with metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer.
04/28/2017
COPD
COPD
FDA Approves First Full Home-Use Wireless Spirometer
04/28/2017
The FDA approved the first spirometer specifically developed for wireless home use for the monitoring of asthma, COPD, and other diseases.
04/28/2017
Neurological Disorders and Diseases
Neurological Disorders and Diseases
FDA Approves New Treatment for Form of Batten Disease
04/27/2017
The US Food and Drug Administration has approved a new option for the treatment of a specific form of Batten disease in pediatric patients aged 3 years and older.
04/27/2017
Liver Disease
Liver Disease
FDA Expands Approved Use of Stivarga
04/27/2017
The FDA has approved the first new option for the treatment of liver cancer, specifically hepatocellular carcinoma, in nearly 10 years.
04/27/2017
opioids
opioids
Abuse-Deterrent Opioid Receives FDA Approval
04/26/2017
The first immediate-release opioid to receive abuse-deterrent labeling was recently approved by the FDA.
04/26/2017
FDA
FDA
FDA Approves First Methotrexate Oral Solution
04/26/2017
The FDA has approved Xatmep, an oral solution for the treatment of acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis.
04/26/2017
Lipids
Lipids
FDA Approves New Dosing Option for Praluent
04/25/2017
The FDA has approved a new, monthly dosing option for the PCSK9-inhibitor Praluent (alirocumab).
04/25/2017
Treatment
Treatment
FDA: New Indication for Thymoglobulin
04/24/2017
The FDA has approved a new indication for the drug Thymoglobulin, for use in patients undergoing kidney transplant.
04/24/2017
FDA
FDA
New Biosimilar Approved by the FDA
04/24/2017
The US Food and Drug Administration recently approved the second biosimilar to Remicade for the treatment of immune-disorders.
04/24/2017